Inhibition of cathepsin s produces neuroprotective effects after traumatic brain injury in mice

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Xu, Jianguo ^a   Wang, Handong ^a   Ding, Ke ^a   Lu, Xinyu ^a   Li, Tao ^a   Wang, Jiawei ^a   Wang, Chunxi ^a   Wang, Jian ^b  

^a NANJING UNIVERSITY   (China)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN S; CATHEPSIN S INHIBITOR; MESSENGER RNA; MORPHOLINUREA LEUCINEHOMOPHENYLALANINE VINYLSULFONE PHENYL; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG; CATHEPSIN; DIPEPTIDE; N MORPHOLINOUREA LEUCINE HOMOPHENYLALANINE PHENYL VINYLSULFONE; N-MORPHOLINOUREA-LEUCINE-HOMOPHENYLALANINE-PHENYL-VINYLSULFONE; SULFONE;

ANIMAL EXPERIMENT; ARTICLE; BRAIN EDEMA; BRAIN NERVE CELL; BRAIN TISSUE; BRAIN WATER; CELLULAR DISTRIBUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROGLIA; MOUSE; NERVE CELL DEGENERATION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; TRAUMATIC BRAIN INJURY; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; BRAIN; BRAIN INJURY; CHEMISTRY; CYTOPLASM; DRUG ANTAGONISM; EDEMA; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; INFLAMMATION; INSTITUTE FOR CANCER RESEARCH MOUSE; MALE; METABOLISM; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; TIME;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; BRAIN INJURIES; CATHEPSINS; CYTOPLASM; DIPEPTIDES; EDEMA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MICE; MICE, INBRED ICR; MICROGLIA; MICROSCOPY, FLUORESCENCE; NEURONS; NEUROPROTECTIVE AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; SULFONES; TIME FACTORS;

EID: 84887389490     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/187873     Document Type: Article

References (52)

1. Lecaille F., Kaleta J., Brömme D., Human and parasitic Papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chemical Reviews 2002 102 12 4459 4488 2-s2.0-0036882393 10.1021/cr0101656
2. Clark A. K., Malcangio M., Microglial signalling mechanisms: cathepsin S and Fractalkine. Experimental Neurology 2012 234 2 283 292 2-s2.0-84858152254 10.1016/j.expneurol.2011.09.012
3. Ärnlv J., Cathepsin S as a biomarker: where are we now and what are the future challenges? Biomarkers in Medicine 2012 6 1 9 11 2-s2.0-84856613892 10.2217/bmm.11.102
4. Small D. M., Burden R. E., Scott C. J., The emerging relevance of the cysteine protease cathepsin S in disease. Clinical Reviews in Bone and Mineral Metabolism 2011 9 2 122 132 2-s2.0-79960062100 10.1007/s12018-011-9095-5
5. Phipps-Yonas H., Semik V., Hastings K. T., GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity. European Journal of Immunology 2013 43 1 65 74
6. Požgan U., Caglič D., Rozman B., Nagase H., Turk V., Turk B., Expression and activity profiling of selected cysteine cathepsins and matrix metalloproteinases in synovial fluids from patients with rheumatoid arthritis and osteoarthritis. Biological Chemistry 2010 391 5 571 579 2-s2.0-77952798828 10.1515/BC.2010.035
7. Williams A. S., Eynott P. R., Leung S.-Y., Nath P., Jupp R., De Sanctis G. T., Resnick R., Adcock I. M., Chung K. F., Role of cathepsin S in ozone-induced airway hyperresponsiveness and inflammation. Pulmonary Pharmacology and Therapeutics 2009 22 1 27 32 2-s2.0-58349121887 10.1016/j.pupt.2008.11.002
8. Taleb S., Cancello R., Poitou C., Rouault C., Sellam P., Levy P., Bouillot J.-L., Coussieu C., Basdevant A., Guerre-Millo M., Lacasa D., Clement K., Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women. Journal of Clinical Endocrinology and Metabolism 2006 91 3 1042 1047 2-s2.0-33644817971 10.1210/jc.2005-1601 (Pubitemid 43357778)
9. Liu J., Ma L., Yang J., Ren A., Sun Z., Yan G., Sun J., Fu H., Xu W., Hu C., Shi G.-P., Increased serum cathepsin S in patients with atherosclerosis and diabetes. Atherosclerosis 2006 186 2 411 419 2-s2.0-33646518541 10.1016/j.atherosclerosis.2005.08.001
10. Spielmann N., Mutch D. M., Rousseau F., Tores F., Hager J., Bertrais S., Basdevant A., Tounian P., Dubern B., Galan P., Clément K., Cathepsin S genotypes are associated with Apo-A1 and HDL-cholesterol in lean and obese French populations. Clinical Genetics 2008 74 2 155 163 2-s2.0-47149095991 10.1111/j.1399-0004.2008.01043.x (Pubitemid 351974276)
11. De Nooijer R., Bot I., Von Der Thüsen J. H., Leeuwenburgh M. A., Overkleeft H. S., Kraaijeveld A. O., Dorland R., Van Santbrink P. J., Van Heiningen S. H., Westra M. M., Kovanen P. T., Jukema J. W., Van Der Wall E. E., Van Berkel T. J. C., Shi G. P., Biessen E. A. L., Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 2 188 194 2-s2.0-59449092755 10.1161/ATVBAHA.108.181578
12. Chen H., Wang J., Xiang M. X., Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling after myocardial infarction. Cardiovascular Research 2013 10.1093/cvr/cvt158
13. Wang B., Sun J., Kitamoto S., Yang M., Grubb A., Chapman H. A., Kalluri R., Shi G.-P., Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. Journal of Biological Chemistry 2006 281 9 6020 6029 2-s2.0-33646827205 10.1074/jbc.M509134200 (Pubitemid 43847703)
14. Chen K.-L., Chang W.-S. W., Cheung C. H. A., Lin C.-C., Huang C.-C., Yang Y.-N., Kuo C.-P., Kuo C.-C., Chang Y.-H., Liu K.-J., Wu C.-M., Chang J.-Y., Targeting cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Letters 2012 317 1 89 98 2-s2.0-84856323422 10.1016/j.canlet. 2011.11.015
15. Pan L., Li Y., Jia L., Qin Y., Qi G., Cheng J., Qi Y., Li H., Du J., Cathepsin S deficiency results in abnormal accumulation of autophagosomes in macrophages and enhances Ang II-induced cardiac inflammation. PLoS ONE 2012 7 4 2-s2.0-84860491083 10.1371/journal.pone.0035315 e35315
16. Huang C. C., Chen K. L., Cheung C. H., Chang J. Y., Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radical Biology & Medicine 2013 10.1016/j.freeradbiomed.2013.07.020
17. Lemere C. A., Munger J. S., Shi G.-P., Natkin L., Haass C., Chapman H. A., Selkoe D. J., The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain: an immunocytochemical study. American Journal of Pathology 1995 146 4 848 860 2-s2.0-0028927279
18. Akahoshi N., Murashima Y. L., Himi T., Ishizaki Y., Ishii I., Increased expression of the lysosomal protease cathepsin S in hippocampal microglia following kainate-induced seizures. Neuroscience Letters 2007 429 2-3 136 141 2-s2.0-36348973410 10.1016/j.neulet.2007.10.007 (Pubitemid 350161122)
19. Wendt W., Lübbert H., Stichel C. C., Upregulation of cathepsin S in the aging and pathological nervous system of mice. Brain Research 2008 1232 7 20 2-s2.0-50849096059 10.1016/j.brainres.2008.07.067
20. Barclay J., Clark A. K., Ganju P., Gentry C., Patel S., Wotherspoon G., Buxton F., Song C., Ullah J., Winter J., Fox A., Bevan S., Malcangio M., Role of the cysteine protease cathepsin S in neuropathic hyperalgesia. Pain 2007 130 3 225 234 2-s2.0-34250873991 10.1016/j.pain.2006.11.017 (Pubitemid 46977115)
21. Clark A. K., Grist J., Al-Kashi A., Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model. Arthritis and Rheumatism 2012 64 6 2038 2047
22. Flierl M. A., Stahel P. F., Beauchamp K. M., Morgan S. J., Smith W. R., Shohami E., Mouse closed head injury model induced by a weight-drop device. Nature Protocols 2009 4 9 1328 1337 2-s2.0-70249097688 10.1038/nprot.2009.148
23. Wang J. W., Wang H. D., Zhong W. Z., Expression and cell distribution of metabotropic glutamate receptor 5 in the rat cortex following traumatic brain injury. Brain Research 2012 1464 73 81
24. Wang J., Doré S., Heme oxygenase-1 exacerbates early brain injury after intracerebral haemorrhage. Brain 2007 130 6 1643 1652 2-s2.0-34250782407 10.1093/brain/awm095 (Pubitemid 47355932)
25. Wang J., Tsirka S. E., Tuftsin fragment 1-3 is beneficial when delivered after the induction of intracerebral hemorrhage. Stroke 2005 36 3 613 618 2-s2.0-14844329885 10.1161/01.STR.0000155729.12931.8f (Pubitemid 40344165)
26. Schmued L. C., Stowers C. C., Scallet A. C., Xu L., Fluoro-Jade C results in ultra high resolution and contrast labeling of degenerating neurons. Brain Research 2005 1035 1 24 31 2-s2.0-13844253258 10.1016/j.brainres.2004.11.054 (Pubitemid 40248533)
27. Bermpohl D., You Z., Korsmeyer S. J., Moskowitz M. A., Whalen M. J., Traumatic brain injury in mice deficient in Bid: effects on histopathology and functional outcome. Journal of Cerebral Blood Flow and Metabolism 2006 26 5 625 633 2-s2.0-33646373685 10.1038/sj.jcbfm.9600258
28. Werner C., Engelhard K., Pathophysiology of traumatic brain injury. British Journal of Anaesthesia 2007 99 1 4 9 2-s2.0-34447527791 10.1093/bja/aem131 (Pubitemid 47072553)
29. Hall E. D., Vaishnav R. A., Mustafa A. G., Antioxidant therapies for traumatic brain injury. Neurotherapeutics 2010 7 1 51 61 2-s2.0-72949115293 10.1016/j.nurt.2009.10.021
30. Singh I. N., Sullivan P. G., Deng Y., Mbye L. H., Hall E. D., Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy. Journal of Cerebral Blood Flow and Metabolism 2006 26 11 1407 1418 2-s2.0-33747137966 10.1038/sj.jcbfm.9600297 (Pubitemid 44629888)
31. Yamashima T., Oikawa S., The role of lysosomal rupture in neuronal death. Progress in Neurobiology 2009 89 4 343 358 2-s2.0-70450222302 10.1016/j.pneurobio.2009.09.003
32. Turk V., Bode W., The cystatins: protein inhibitors of cysteine proteinases. FEBS Letters 1991 285 2 213 219 2-s2.0-0025817602 10.1016/0014-5793(91)80804-C
33. Dutcher S. A., Underwood B. D., Walker P. D., Diaz F. G., Michael D. B., Patterns of immediate early gene mRNA expression following rodent and human traumatic brain injury. Neurological Research 1999 21 3 234 242 2-s2.0-0032963126 (Pubitemid 29205441)
34. Hayes R. L., Yang K., Raghupathi R., McIntosh T. K., Changes in gene expression following traumatic brain injury in the rat. Journal of Neurotrauma 1995 12 5 779 790 2-s2.0-0028785150
35. Sanz O., Acarin L., González B., Castellano B., NF- B and I b expression following traumatic brain injury to the immature rat brain. Journal of Neuroscience Research 2002 67 6 772 780 2-s2.0-0037085571 10.1002/jnr.10140 (Pubitemid 34226289)
36. Yang K., Mu X. S., Xue J. J., Whitson J., Salminen A., Dixon C. E., Liu P. K., Hayes R. L., Increased expression of c-fos mRNA and AP-1 transcription factors after cortical impact injury in rats. Brain Research 1994 664 1-2 141 149 2-s2.0-0028172846 10.1016/0006-8993(94)91964-X (Pubitemid 24347606)
37. Riese R. J., Wolf P. R., Brömme D., Natkin L. R., Villadangos J. A., Ploegh H. L., Chapman H. A., Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996 4 4 357 366 2-s2.0-0029931108 10.1016/S1074-7613(00)80249-6 (Pubitemid 26174051)
38. Shi G. P., Villadangos J. A., Dranoff G., Small C., Lijuan G., Haley K. J., Riese R., Ploegh H. L., Chapman H. A., Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999 10 2 197 206 2-s2.0-0033083688 (Pubitemid 29115625)
39. Hsieh C.-S., DeRoos P., Honey K., Beers C., Rudensky A. Y., A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. Journal of Immunology 2002 168 6 2618 2625 2-s2.0-0037087364 (Pubitemid 34211636)
40. Honey K., Rudensky A. Y., Lysosomal cysteine proteases regulate antigen presentation. Nature Reviews Immunology 2003 3 6 472 482 2-s2.0-0037805704 10.1038/nri1110 (Pubitemid 37339187)
41. Das M., Mohapatra S., Mohapatra S. S., New perspectives on central and peripheral immune responses to acute traumatic brain injury. Journal of Neuroinflammation 2012 9 1 236
42. Siesjö P., Cederberg D., What has inflammation to do with traumatic brain injury? Child's Nervous System 2010 26 2 221 226 2-s2.0-77949266509 10.1007/s00381-009-1029-x
43. Woodcock T., Morganti-Kossmann M. C., The role of markers of inflammation in traumatic brain injury. Frontiers in Neurology 2013 4 1 18
44. Donkin J. J., Vink R., Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments. Current Opinion in Neurology 2010 23 3 293 299 2-s2.0-77951971088 10.1097/WCO.0b013e328337f451
45. Elliott M. B., Tuma R. F., Amenta P. S., Barbe M. F., Jallo J. I., Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. Journal of Neurotrauma 2011 28 6 973 981 2-s2.0-79959729749 10.1089/neu.2010.1672
46. Chen S.-F., Hsu C.-W., Huang W.-H., Wang J.-Y., Post-injury baicalein improves histological and functional outcomes and reduces inflammatory cytokines after experimental traumatic brain injury. British Journal of Pharmacology 2008 155 8 1279 1296 2-s2.0-57349151570 10.1038/bjp.2008.345
47. Cattaruzza F., Lyo V., Jones E., Pham D., Hawkins J., Kirkwood K., Valdez-Morales E., Ibeakanma C., Vanner S. J., Bogyo M., Bunnett N. W., Cathepsin S is activated during colitis and causes visceral hyperalgesia by a PAR2-dependent mechanism in mice. Gastroenterology 2011 141 5 1864 1874 2-s2.0-80054846758 10.1053/j.gastro.2011.07.035
48. Riese R. J., Mitchell R. N., Villadangos J. A., Shi G.-P., Palmer J. T., Karp E. R., De Sanctis G. T., Ploegh H. L., Chapman H. A., Cathepsin S activity regulates antigen presentation and immunity. Journal of Clinical Investigation 1998 101 11 2351 2363 2-s2.0-0032103322 (Pubitemid 28270429)
49. Palmer J. T., Rasnick D., Klaus J. L., Brömme D., Vinyl sulfones as mechanism-based cysteine protease inhibitors. Journal of Medicinal Chemistry 1995 38 17 3193 3196 2-s2.0-0029099619
50. Clark A. K., Yip P. K., Malcangio M., The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. Journal of Neuroscience 2009 29 21 6945 6954 2-s2.0-66149186748 10.1523/JNEUROSCI.0828-09.2009
51. Chen J. W. Y., Ruff R. L., Eavey R., Wasterlain C. G., Posttraumatic epilepsy and treatment. Journal of Rehabilitation Research and Development 2009 46 6 685 696 2-s2.0-73349116496 10.1682/JRRD.2008.09.0130
52. Pitkänen A., Immonen R. J., Gröhn O. H. J., Kharatishvili I., From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options. Epilepsia 2009 50 2, supplement 21 29 2-s2.0-58849126884 10.1111/j.1528-1167.2008.02007.x